FDA issues risk management guidance

FDA issued three draft guidance documents for industry on how to manage risk throughout the lifecycle of a compound, including its development, the review and approval process, and after it is available on the market. In a conference call, Steven Galson, acting CDER director, said the guidance documents did not require any new risk management activities by companies but were developed to provide greater transparency on the process. ...